A Phase 2b Study, Multicentre, Multinational, Placebo-controlled, Double-blind, Dose-finding Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804

Trial Profile

A Phase 2b Study, Multicentre, Multinational, Placebo-controlled, Double-blind, Dose-finding Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs BPS 804 (Primary)
  • Indications Osteogenesis imperfecta
  • Focus Therapeutic Use
  • Acronyms ASTEROID
  • Sponsors Mereo BioPharma
  • Most Recent Events

    • 08 Aug 2017 According to Mereo BioPharma media release, top-line data from this study is expected in mid-2018.
    • 03 May 2017 Status changed from not yet recruiting to recruiting.
    • 13 Apr 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top